Synonym
Radequinil; AC-3933; AVE-3933; SX-3933; AC3933; AVE3933; SX3933; AC 3933; AVE 3933; SX 3933
IUPAC/Chemical Name
5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
InChi Key
JQOFKKWHXGQABB-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23)
SMILES Code
O=C1NC2=C(C(C3=CC=CC(OC)=C3)=NC=C2)C=C1C4=NOC(C)=N4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
334.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Hashimoto T, Hatayama Y, Nakamichi K, Yoshida N. Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice. Eur J Pharmacol. 2014 Dec 15;745:123-8. doi: 10.1016/j.ejphar.2014.10.015. PubMed PMID: 25446931.
2: Hashimoto T, Iwamura Y. AC-3933, a benzodiazepine partial inverse agonist, improves memory performance in MK-801-induced amnesia mouse model. Pharmacol Biochem Behav. 2016 May;144:45-52. doi: 10.1016/j.pbb.2016.03.001. PubMed PMID: 26946254.
3: Hatayama Y, Hashimoto T, Kohayakawa H, Kiyoshi T, Nakamichi K, Kinoshita T, Yoshida N. In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer's disease. Neuroscience. 2014 Apr 18;265:217-25. doi: 10.1016/j.neuroscience.2014.01.063. PubMed PMID: 24513386.
4: Hashimoto T, Kiyoshi T, Kohayakawa H, Iwamura Y, Yoshida N. Pharmacological properties of AC-3933, a novel benzodiazepine receptor partial inverse agonist. Neuroscience. 2014 Jan 3;256:352-9. PubMed PMID: 24505610.
5: Mise M, Yadera S, Matsuda M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos. 2004 Feb;32(2):240-5. PubMed PMID: 14744947.
6: Mise M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics. 2004 Nov;14(11):769-73. PubMed PMID: 15564884.
